Cowen & Co. Keeps Their Buy Rating on Allena Pharmaceuticals Inc (ALNA)

By Jason Carr

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Allena Pharmaceuticals Inc (ALNAResearch Report) yesterday. The company’s shares closed yesterday at $5.74, close to its 52-week low of $4.80.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.5% and a 52.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allena Pharmaceuticals Inc with a $30.50 average price target.

See today’s analyst top recommended stocks >>

Based on Allena Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.61 million. In comparison, last year the company had a GAAP net loss of $7.88 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.